4/A: Lexeo CEO Amends Stock Sale for Tax Obligations

Lexeo Therapeutics CEO Richard Nolan Townsend amended a Form 4 filing, correcting the number of shares sold to cover tax obligations on restricted stock units.

Summary

• Richard Nolan Townsend, Chief Executive Officer and Director of Lexeo Therapeutics, Inc. (LXEO), filed an amendment (Form 4/A) to a previously reported insider transaction.
• The amendment corrects the number of common stock shares disposed of on August 18, 2025.
• The original Form 4, filed on August 20, 2025, inadvertently reported the disposition of 2,735 securities.
• The corrected number of shares disposed is 1,115 shares of Common Stock.
• The sale was executed at a price of $4.668 per share.
• The purpose of this transaction was to cover tax obligations arising from the release of restricted stock units (RSUs).
• Following this corrected transaction, Mr. Townsend beneficially owns 220,058 shares, which includes 131,092 Restricted Stock Units.

Sentiment

Score: 5

Explanation: The filing is a factual correction of a previous insider transaction, indicating no material change in company outlook or performance. It is a neutral event.

Future Outlook

This filing is a correction of an insider transaction and does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This filing is a routine insider transaction amendment, common for executives managing equity compensation and tax obligations. It does not provide insights into broader industry trends or competitive positioning.

Stakeholder Impact

• Minimal impact on shareholders as this is a routine correction of an insider's tax-related stock sale, not indicative of a change in company fundamentals or management's confidence.

Key Dates

Recommendation

This filing is an amendment to correct a previous insider transaction related to tax obligations on restricted stock units. It does not provide new information regarding the company's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. The transaction itself is routine for executives receiving equity compensation, and the correction does not alter the fundamental investment thesis for Lexeo Therapeutics.

Keywords

Lexeo Therapeutics, LXEO, Form 4/A, insider transaction, stock sale, CEO, Richard Nolan Townsend, restricted stock units, tax obligations, equity compensation